BeStock  
Stocks › Biotechnology › ABCL

AbCellera Biologics ABCL

US equityMarket cap rank #2395BiotechnologyAI medical concept stocks
$9.69 −$0.78 (-7.45%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $9.73 +0.41%
Open$10.14
Prev close$10.47
Day range$9.58 – $10.26
Volume4.25M
Market cap$3.16B
P/E (TTM)–
Dividend yield–

Price chart

Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, or Bollinger Bands for the same 20-day/2-standard-deviation channel used in the Technical signals table.

ABCL at a glance

AbCellera Biologics (ABCL) is trading at $9.69, down 7.45% on the day. Its market value of $3.16B makes it the 2395th largest of the 3753 companies we follow.

Over the past 52 weeks it has traded between $2.75 and $15.02, so it sits 35.5% below the top of that range. Holders are ahead 176.1% over twelve months, but down 8.7% across the last three months.

Price is below the 50-day average ($12.30) but above the 200-day ($7.42); RSI is 34, and the last 30 sessions moved at roughly 80% annualized volatility.

In the quarter ended Sep 2026 the company brought in $10.64M of revenue, up 18.8% from a year earlier, and a net loss of $40.76M.

9 analysts follow the stock and the average call is "buy". The mean target, $19.33, sits 99.5% over where the stock trades.

This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.

Key statistics

Bid / Ask$9.68 / $9.73
Average price today$9.86
Volume4.25MAvg (90d) 5.64M
Turnover$41.88M
Turnover rate1.89%of shares outstanding
Volume ratio1.63vs. recent average pace
Day amplitude6.50%
Market cap$3.16B
Float market cap$2.17B
Shares outstanding224.45M
EPS (TTM)-$0.49
P/B2.98
Book value / share$3.25
Net profit (TTM)-$160.04M
Net assets$1.06B
30-day volatility80.2%annualized
Avg daily range (ATR)9.37%of price, 14 days
Max drawdown (1y)-40.1%-34.6% from 1y peak

Quote as of Nov 20, 2026 8:10 pm ET. Prices can lag the live tape. This is background information, not a recommendation.

BeStock Grade

C
BeStock Grade

Composite of 3 factors below, ranked against the 3734 U.S. stocks BeStock covers.

A
Valuation

Cheaper than usual on its own 5-year P/E history scores higher.

D
Momentum

Trading closer to its 52-week high than most peers scores higher.

B
Wall Street

9 analysts, consensus Buy.

How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.

Six-factor research snapshot

Overall percentile: 79.2 · 2026-11-22 14:27 UTC. Higher values indicate a stronger relative ranking.

FactorPercentile
Valuation—
Growth50.9
Profitability22.5
Momentum73.6
Financial health93.3
Analyst view86.6

Price forecast

What Wall Street analysts and Morningstar's fair-value model expect for the stock

Analyst price target (avg)$19.33+99.5% vs. current price
Consensus ratingBuy9 analysts covering
Morningstar fair value$15.18Price is below fair value

Wall Street’s average 12-month target is $19.33, 99.5% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $15.18, so shares trade 36.2% below that estimate. On earnings multiple, it sits in the 6th percentile of its own five-year valuation range (cheaper than usual).

Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.

Performance

Price return over each window, from adjusted daily and weekly closes

1 day
-7.4%
1 week
-15.7%
1 month
-14.8%
3 months
-8.7%
6 months
+86.3%
Year to date
+183.3%
1 year
+176.1%
Day range
$9.58$10.26
52-week range
$2.75$15.02

Technical signals

Full technicals →
Trend readLeaning bearish

2 bullish · 4 bearish of 7 signals

IndicatorValueSignal
Price vs 20-day average-17.8%Bearish
Price vs 50-day average-21.2%Bearish
Price vs 200-day average+30.6%Bullish
50-day vs 200-day50d above 200dBullish
RSI (14)33.9Bearish
MACD (12,26,9)-0.47Bearish
Bollinger band position-6%Neutral

Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.

How ABCL ranks on BeStock

Market value#2385 of 3734
Closeness to 52-week high#2468 of 3724
Dollar volume today#1544 of 3734

Ranks are among the 3,734 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.

ABCL is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.

Since 2020-12-28, the strategy has returned 401.7% (183.6% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated daily — not a guarantee of future results, and not a BeStock recommendation.

Strategy Backtest

Pick a strategy above and run the backtest to see its simulated performance on ABCL.

Rule-based technical strategies computed from this stock’s own price history only. Signals use only data available through the prior trading day (no look-ahead), and trading costs, slippage and taxes aren’t modeled. A backtested rule performing well in the past is not a guarantee of future results — this is an educational illustration, not investment advice.

Community Sentiment on ABCL

No votes yet — be the first to weigh in.

Reader sentiment, not investment advice. One vote per visitor; click again to change it.

ABCL stock: common questions

Where is ABCL trading right now?

$9.69 is the latest print for ABCL, a move of -7.45% against yesterday's close of $10.47. Today's low and high so far: $9.58 and $10.26.

How big is AbCellera Biologics?

Equity value comes to $3.16B at the current price. By that measure it is number 2395 of the 3753 names in our coverage.

Where does ABCL sit in its 52-week range?

The year's floor is $2.75 and the ceiling $15.02. Shares are 35.5% away from that ceiling.

Does ABCL send cash back through a dividend?

Our data shows no dividend paid by AbCellera Biologics over the trailing twelve months.

Do Wall Street analysts like ABCL?

Of 9 analysts, 89% say buy, 11% hold and 0% sell. Price targets average $19.33, with the most cautious at $14.00 and the most optimistic at $30.00.

BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.

Discussion

No comments yet — be the first to weigh in on ABCL.

Sign in to join the discussion.

Scroll to Top